What is it about?
After 24 months, women with PHPT had greater reduction of alkaline phosphatase, higher increase of FN/TH-BMD versus subjects affected by primary osteoporosis. A significant increase in BMD was more frequent in women with primary hyperparathyroidism than in those with primary osteoporosis.
Featured Image
Why is it important?
This is the first published paper assessing that Denosumab therapy is effective in older women with PHPT-related osteoporosis.
Perspectives
These results open the possibility to expand our therapeutic armamentarium for patients with primary hyperparathyroidism, with potential positive efficacy in controlling both bone turnover and bone mass, reducing consequently the risk for fragility fractures.
Dr. ALBERTO FALCHETTI
Endosmet, Villa Donatello, Private Hospital, FLorence, Italy
Read the Original
This page is a summary of: Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism, Journal of the American Geriatrics Society, January 2018, Wiley,
DOI: 10.1111/jgs.15250.
You can read the full text:
Contributors
The following have contributed to this page
